Ownership Summary
Quarter ending 30 Jun, 2026
iSpecimen Inc. (NASDAQ:ISPC) has 11 institutional investors that have filed 13F reports for the period ending March 2026.
- Collectively, these holders controlled 3.9% of iSpecimen's outstanding shares in March 2026, up from 2.8% in December 2025.
- Their total shares held in ISPC increased 642.1% from the prior quarter, while the number of investors in iSpecimen increased 22.22% year over year.
- Of these 11 holders, 8 added to their stakes in iSpecimen, 1 trimmed positions, and 2 made no changes.
- Altogether, these fund groups held 13.29K shares in ISPC by March 2026, up by 11.5K shares quarter on quarter, and up 11.79K shares year over year.
- GEODE CAPITAL MANAGEMENT, LLC leads ownership in ISPC with 7.83K shares as of March 31, 2026, equal to 2.29% of outstanding shares.
- The most significant purchases of ISPC for the quarter ending March 2026 came from GEODE CAPITAL MANAGEMENT, LLC (6.79K), CITADEL ADVISORS LLC (1.26K), UBS Group AG (1.18K), JANE STREET GROUP, LLC (1.04K), VANGUARD FIDUCIARY TRUST CO (704).
- The biggest sellers of iSpecimen for the quarter ending March 2026 included Tower Research Capital LLC (TRC) (0).
- Per Business Quant, the top 10 investors in ISPC for the quarter ending March 2026 include GEODE CAPITAL MANAGEMENT, LLC (7.83K), JANE STREET GROUP, LLC (1.39K), UBS Group AG (1.34K), CITADEL ADVISORS LLC (1.26K), VANGUARD FIDUCIARY TRUST CO (704), StoneX Group Inc. (492), Tower Research Capital LLC (TRC) (166), BlackRock, Inc. (70), VANGUARD CAPITAL MANAGEMENT LLC (30), SBI Securities Co., Ltd. (0).